Safety and Efficacy of BARS13 in the Elderly

NCT04681833 | Completed Phase 2 DMC

• 1 other identifier: ADVA-BARS13-002
• Study Type: interventional
• Target: 125
• Locations: 1 country
• Sites: 2

Brief Summary

Advaccine Clinical Research are developing a vaccine called BARS13 for the active immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old) for the seasonal prevention of Respiratory Syncytial Virus (RSV) infection. A total of 125 volunteers aged 60 - 80 years (inclusive) will be enrolled in this study, and will be divided into 3 groups (or 'cohorts') of 40 people (cohort 1 and 2) and 45 people (cohort 3). The aim of the study is to evaluate the safety and tolerability of BARS13 in this age group.

Conditions

Respiratory Syncytial Virus Infections

Keywords

Respiratory Syncytial Virus (RSV); BARS13; Vaccines; Virus Diseases

Outcome Measures

Primary Outcomes (9)

• Incidence and severity of vaccine-related AEs, including the following solicited AEs

  Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.

  From baseline (Day 1) to the end of Day 7.

• Incidence and severity of vaccine-related AEs, including the following solicited AEs

  Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.

  From Day 28 to the end of Day 35.

• Incidence and severity of vaccine-related AEs, including the following solicited AEs

  Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.

  From Day 57 to the end of Day 64 (only for multiple high repeat dose group).

• Occurrence of AEs

  An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.

  From baseline (Day 1) to the end of the 7-day, 28-day follow up period after each vaccination

• Occurrence of any AE during a 60-minute post-vaccination safety observation period

  An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.

  On Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)

• Occurrence of any AE leading to withdrawal

  An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.

  During the 28-day follow up period after each vaccination

• Occurrence of any serious adverse event (SAE)

  A SAE is any untoward medical occurrence that, at any dose: • Results in death; • Is life-threatening, (NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event/reaction in which the participant was at risk of death at the time of the event/reaction; it does not refer to an event/reaction which hypothetically might have caused death, if it were more severe); • Requires inpatient hospitalization or prolongation of an existing hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Is a medically important event or reaction.

  From baseline (Day 1) to the last visit, assessed up to 14 months

• Occurrence of any clinically significant clinical laboratory abnormalities

  Measured as Toxicity Grade ≥1.

  From baseline (Day 1) to the last visit, assessed up to 14 months

• Treatment-emergent, clinically significant changes in vital signs and physical examinations.

  Vital signs include systolic and diastolic blood pressures, respiratory rate, pulse rate and oral temperature.

  At specified intervals after each vaccination on Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)

Secondary Outcomes (4)

• Humoral response to BARS13

  Prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only)

• Humoral response to BARS13

  At follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose

• Humoral response to BARS13

  Prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only)

• Humoral response to BARS13

  At follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose

Other Outcomes (5)

• Blood samples for exploratory immunological analyses

  On Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)

• Blood samples for exploratory immunological analyses

  On Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)

• Blood samples for exploratory immunological analyses

  In participants presenting with symptoms to the general practitioner from baseline (Day 1) to the last visit, assessed up to 14 months

Study Arms (6)

Cohort 1: BARS13 low repeat dose

EXPERIMENTAL

Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.

Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo

Cohort 1: BARS13 placebo low repeat dose

PLACEBO COMPARATOR

Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.

Drug: Placebo

Cohort 2: BARS13 high repeat dose

EXPERIMENTAL

Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.

Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)

Cohort 2: BARS13 placebo high repeat dose

PLACEBO COMPARATOR

Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.

Drug: Placebo

Cohort 3: BARS13 high repeat multiple dose

EXPERIMENTAL

Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.

Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)

Cohort 3: BARS13 placebo high repeat multiple dose

PLACEBO COMPARATOR

Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.

Drug: Placebo

Interventions

Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo DRUG

Low Repeat Dose

Cohort 1: BARS13 low repeat dose

Recombinant Respiratory Syncytial Virus Vaccine (BARS13) DRUG

High Repeat Dose/High Repeat Multiple Dose

Cohort 2: BARS13 high repeat dose; Cohort 3: BARS13 high repeat multiple dose

Placebo DRUG

Liquid diluent/Lyophilised Powder

Cohort 1: BARS13 placebo low repeat dose; Cohort 2: BARS13 placebo high repeat dose; Cohort 3: BARS13 placebo high repeat multiple dose

Eligibility Criteria

• Age: 60 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants who meet all of the following criteria at screening are eligible to participate in the study:
• Healthy male or female adults, or adults with stable chronic disease aged 60 to 80 years old, inclusive. Stable disease includes adults with no new diagnosis, hospitalization or changes in medication in the preceding 3 months. Adults with stable, Stage 1 chronic obstructive pulmonary disease (COPD) are eligible for this study provided they are not using inhaled or systemic corticosteroids.
• Body mass index (BMI) ≤40 kg/m2.
• Screening 12-lead electrocardiogram (ECG) must be within normal range (QT interval corrected using Fridericia's formula \[QTcF\] males ≤ 450 msec; females ≤ 470 msec) or with abnormalities, which are not hazardous to the patient according to the opinion of the Investigator at the screening visit.
• Hematology, serum chemistry, coagulation and urinalysis test results not deviating from the normal reference range by age and gender to a clinically relevant extent at screening.
• Systolic blood pressure in the range of 90 to 160 mmHg (inclusive) and diastolic blood pressure in the range of 50 to 95 mmHg (inclusive) after 5 minutes in supine position at the screening visit. (May be repeated twice, if abnormal values were recorded in the first instance, at the discretion of the PI).
• Willing and able (on both a physical and cognitive basis) to give informed consent prior to study enrolment.
• Able to comply with study requirements, including access to transportation for study visits.
• Access to inbound and outbound telephone communication with caregivers and study staff.
• Males must be surgically sterile (\>30 days since vasectomy with no viable sperm), abstinent or, if engaged in sexual relations with a person of child-bearing potential, the participant and his partner must use an acceptable, highly effective, contraceptive method from screening and for a period of at least 3 months after the last dose of study drug. Acceptable methods of contraception are the use of condoms and an effective contraceptive for the female partner that could include surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, or intrauterine contraception/device. The PI or appropriate designee is to assess the adequacy of methods of contraception on a case-by-case basis.
• Females must be of nonchildbearing potential i.e., surgically sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before screening) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone level ≥40 IU/L at the screening visit).

You may not qualify if:

• Participants who meet any of the following criteria are not eligible to participate in the study:
• Participation in research involving investigational product (IP) (drug / biologic / device) within 45 days before the planned date of the Day 1 vaccination.
• History of a serious reaction to any prior vaccination.
• Received any vaccine other than an inactivated or live attenuated influenza vaccine or coronavirus SARS-COV-2 (COVID-19) vaccine (not in a clinical trial setting) in the 4 weeks preceding the first study vaccination; or any RSV vaccine at any time or who plan to receive any non-study vaccines within 28 days of the last dose of study vaccine. Influenza vaccine and coronavirus SARS-COV-2 (COVID-19) vaccine should not be given within 14 days of each dose of study vaccine.
• Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
• Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical and nasal glucocorticoids will be permitted.
• Positive testing for active HIV, HBsAg, HCV, Quantiferon (TB infection).
• Positive urine drug screen at screening, or pre-vaccination for any drug of abuse unless there is an explanation acceptable to the PI (e.g., the participant stated in advance that they consumed a prescription or over the counter product which contained the detected drug) and/or the participant had a negative urine drug screen on retest by the pathology laboratory.
• A positive alcohol breathalyzer test at screening or pre-vaccination.
• Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
• Acute disease at the time of enrolment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥38.0°C on the planned day of vaccine administration).
• Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse (regular consumption of \> 10 units of alcohol/week \[men and women\]; 1 unit = 237 mL of beer, 25 mL shot of 40% spirit or a 125 mL glass of wine. A standard drink contains 10 g of alcohol).
• Birthmarks, tattoos, wound or other skin conditions over the deltoid region of either arm that, in the PI's opinion, could reasonably obscure and interfere with evaluation of local injection site reactions.
• Subject with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura, autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (Type 1), Crohn's disease or ulcerative colitis.
• Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic, cognitive, or psychiatric conditions deemed likely to impair the quality of study compliance or safety reporting).

Sponsors & Collaborators

• Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.: lead

Study Sites (2)

Q-Pharm Pty Ltd

Herston, Queensland, 4006, Australia

Location

CMAX Clinical Research

Adelaide, South Australia, Australia

Location

MeSH Terms

Conditions

Respiratory Syncytial Virus Infections; Virus Diseases

Condition Hierarchy (Ancestors)

Pneumovirus Infections; Paramyxoviridae Infections; Mononegavirales Infections; RNA Virus Infections; Infections

Study Officials

• Natasha Martin, MBBS

  CMAX Clinical Research Pty Ltd

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: This study is double-blinded. Sealed participant-specific code break envelopes will be produced by the unblinded statistician so that the treatment assigned to each participant can be obtained if required, in an emergency only, where knowledge of the randomisation code is required to provide appropriate treatment. The code break envelopes will be retained at the clinical unit in a secure, accessible location. Those blinded to study drug assignment include the sponsor, the PI, clinical study personnel participating in participants' care or clinical evaluations, and the study participants.
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29. Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29. Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57. Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.

Study Record Dates

• First Submitted: December 14, 2020
• First Posted: December 23, 2020
• Study Start: May 24, 2021
• Primary Completion: January 26, 2024
• Study Completion: April 2, 2024
• Last Updated: September 20, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

AU (2)